Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
HemaSphere · 2025-06 · 9 (6)
DOI: 10.1002/hem3.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 15.06.2025. Verfasst von Patrick Born und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hemostaseology and Cellular Therapy University Hospital Leipzig Leipzig Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, European Commission, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
PET/CT plays an important role in staging of multiple myeloma (MM) and detecting extramedullary disease (EMD); however, its role in patients treated with commercially available CAR T cell therapies is unclear. We evaluated 61 patients treated with CAR T cell products. In 53 patients, PET/CT was available before CAR T infusion, and 43 had follow‐up PET/CT on day 30. Findings from PET/CT were correlated to (CAR) T single‐cell dynamics, fitness and T cell receptor diversity after infusion, and serological markers of tumor burden and inflammation. Patients with bone‐independent EMD had inferior median progression‐free survival (PFS: 3 vs. 15 months, p = 0.01). Univariate and multivariate analysis showed that EMD but not the number of lesions or metabolic tumor volume (MTV) were associated with inferior PFS. High MTV was connected to higher baseline sBCMA and Interleukin‐6 levels, but not associated with hampered CAR T cell expansion or decreased fitness of the bystander T cell compartment. Follow‐up PET/CTs identified patients with metabolic complete remissions, which were associated with better PFS. PET/CT identifies patients with high risk of relapse after CAR T cell therapy.
Autor:innen und Institutionen
- Department of Hematology, Hemostaseology and Cellular Therapy University Hospital Leipzig Leipzig Germany.
- Fraunhofer Institute for Cell Therapy and Immunology IZI Leipzig Germany.
- Department of Radiology University Hospital Leipzig Leipzig Germany.
- Department of Clinical Immunology University Hospital Leipzig Leipzig Germany.
- Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics University Hospital Leipzig Leipzig Germany.
- Leipzig Medical Biobank Leipzig Germany.
ORCID-Profile: Madlen Jentzsch, Vladan Vucinic, Maximilian Merz
Förderung
- NCI NIH HHS
- European Commission
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Born, P., Fandrei, D., Wang, S. Y., Perez-Fernandez, C., Fischer, L., Ussmann, J., Bach, E., Hoffmann, S., Metzeler, K. H., Herling, M., Herling, C., Jentzsch, M., Boldt, A., Seiffert, S., Baber, R., Weidner, H., Franke, G. N., Denecke, T., Sabri, O., …, & Merz, M. (2025). Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma. HemaSphere, 9(6). https://doi.org/10.1002/hem3.70159
Vancouver
Born P, Fandrei D, Wang SY, Perez-Fernandez C, Fischer L, Ussmann J, et al. Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma. HemaSphere. 2025;9(6). doi:10.1002/hem3.70159
BibTeX
@article{Born2025,
author = {Born, Patrick and Fandrei, David and Wang, Song Yau and Perez-Fernandez, Carmen and Fischer, Luise and Ussmann, Jule and Bach, Enrica and Hoffmann, Sandra and Metzeler, Klaus H and Herling, Marco and Herling, Carmen and Jentzsch, Madlen and Boldt, Andreas and Seiffert, Sabine and Baber, Ronny and Weidner, Heike and Franke, Georg-Nikolaus and Denecke, Timm and Sabri, Osama and Platzbecker, Uwe and Vucinic, Vladan and Meyer, Hans Jonas and Kurch, Lars and Merz, Maximilian},
title = {Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {6},
doi = {10.1002/hem3.70159}
}
EUVIMED